These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33972223)

  • 1. Anticraving medication for moderate to severe alcohol use disorder.
    Mong J; Ahamad K; Bach P
    CMAJ; 2021 May; 193(19):E695. PubMed ID: 33972223
    [No Abstract]   [Full Text] [Related]  

  • 2. SAEM GRACE: Anti-craving medications for alcohol use disorder treatment in the emergency department: A systematic review of direct evidence.
    Punia K; Scott W; Manuja K; Sabbineni M; Campbell K; Balodis IM; MacKillop J
    Acad Emerg Med; 2024 May; 31(5):504-514. PubMed ID: 37735346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges.
    Brünen S; Bekier NK; Hiemke C; Korf F; Wiedemann K; Jahn H; Kiefer F
    Alcohol Alcohol; 2019 Jan; 54(1):51-55. PubMed ID: 30260366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticraving therapy for alcohol use disorder: A clinical review.
    Shen WW
    Neuropsychopharmacol Rep; 2018 Sep; 38(3):105-116. PubMed ID: 30175522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very Low Frequency of Drug Therapy of Alcohol Dependence in Germany - Analysis of Data of A Statutory Health Insurance.
    Scherbaum N; Holzbach R; Stammen G; Kirchof U; Bonnet U
    Pharmacopsychiatry; 2020 Jan; 53(1):37-39. PubMed ID: 31132796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.
    Mann K; Roos CR; Hoffmann S; Nakovics H; Leménager T; Heinz A; Witkiewitz K
    Neuropsychopharmacology; 2018 Mar; 43(4):891-899. PubMed ID: 29154368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].
    Gahr M; Kölle MA; Schönfeldt-Lecuona C
    Nervenarzt; 2013 May; 84(5):584-9. PubMed ID: 22892944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence Across FDA-Approved Medications for Alcohol Use Disorder in a Veterans Administration Population.
    Walker JR; Korte JE; McRae-Clark AL; Hartwell KJ
    J Stud Alcohol Drugs; 2019 Sep; 80(5):572-577. PubMed ID: 31603760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls.
    Fairbanks J; Umbreit A; Kolla BP; Karpyak VM; Schneekloth TD; Loukianova LL; Sinha S
    Mayo Clin Proc; 2020 Sep; 95(9):1964-1977. PubMed ID: 32446635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of healthcare utilization among patients treated with alcoholism medications.
    Mark TL; Montejano LB; Kranzler HR; Chalk M; Gastfriend DR
    Am J Manag Care; 2010; 16(12):879-88. PubMed ID: 21348558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.
    Chaignot C; Zureik M; Rey G; Dray-Spira R; Coste J; Weill A
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1239-1248. PubMed ID: 30251424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.
    Littleton J; Zieglgänsberger W
    Am J Addict; 2003; 12(s1):s3-s11. PubMed ID: 14972776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.
    Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
    Alcohol Clin Exp Res; 2011 Mar; 35(3):523-31. PubMed ID: 21143249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acamprosate-induced myoclonic jerks: A rare side effect.
    Soni PK; Singh LK; Das S; Nandan NK
    Indian J Pharmacol; 2021; 53(6):511-512. PubMed ID: 34975141
    [No Abstract]   [Full Text] [Related]  

  • 15. Medications and alcohol craving.
    Swift RM
    Alcohol Res Health; 1999; 23(3):207-13. PubMed ID: 10890816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate.
    Umhau JC; Schwandt ML; Usala J; Geyer C; Singley E; George DT; Heilig M
    Neuropsychopharmacology; 2011 May; 36(6):1178-86. PubMed ID: 21289601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
    Soyka M; Chick J
    Am J Addict; 2003; 12(s1):s69-s80. PubMed ID: 14972781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
    Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
    Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
    Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
    Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder.
    Petrakis IL; Poling J; Levinson C; Nich C; Carroll K; Ralevski E; Rounsaville B
    Biol Psychiatry; 2006 Oct; 60(7):777-83. PubMed ID: 17008146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.